82 DOVETAIL vamikibart – while intravitreal IL-6 monotherapy is helpful, 50% of patients have persistent IRF Sharma S, et al. A Novel Intravitreal Anti-IL-6 Monoclonal Antibody for Uveitic Macular Edema (UME): Preliminary Results From the Phase 1 DOVETAIL Study. Presented at the American Society of Retina Specialists, Seattle, WA, July 28 – August 1, 2023; Persistent intraretinal fluid (IRF) is known to cause permanent negative effects on visual function DOVETAIL vamikibart Absence of IRF DOVETAIL vamikibart Absence of SRF ~50% of patients have persistent IRF